Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lamin B2 is a type V intermediate filament protein encoded by the LMNB2 gene. It is a major component of the nuclear lamina—a filamentous meshwork adjacent to the inner nuclear membrane—which confers structural stability to the nucleus and participates in chromatin organization and gene expression. Lamin B2 is essential for maintaining nuclear mechanics during development, especially neuronal migration and brain organogenesis. LMNB2 promotes cell cycle progression and proliferation, and its overexpression is implicated in several cancers, including triple-negative breast cancer and colorectal cancer. LMNB2 is also linked to rare genetic conditions such as progressive myoclonic epilepsy and microcephaly. While currently not directly targeted by approved drugs, LMNB2 represents an emerging therapeutic and biomarker target in oncology and neurodevelopmental research
No mechanism established for clinical drugs targeting LMNB2 directly; experimental silencing approaches (e.g., shRNA, siRNA) decrease LMNB2 expression and suppress tumor proliferation/apoptosis in cancer models
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lamin B2 (LMNB2).